Top Page
BioCardia
(NASDAQ:BCDA)
BioCardia (BCDA) vs. SPDR S&P 500 ETF (SPY)
BioCardia Business Overview & Revenue Model
BioCardia Earnings Call Summary
BioCardia Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 58.00K | 58.00K | 477.00K | 1.35M | 1.01M | 145.00K |
| Gross Profit | -431.00K | -372.00K | 66.00K | 975.00K | 375.00K | 141.00K |
| EBITDA | -8.71M | -7.93M | -11.56M | -11.82M | -12.57M | -14.44M |
| Net Income | -8.79M | -7.95M | -11.57M | -11.91M | -12.62M | -15.00M |
Balance Sheet | ||||||
| Total Assets | 2.09M | 3.72M | 2.99M | 9.79M | 15.72M | 23.42M |
| Cash, Cash Equivalents and Short-Term Investments | 980.00K | 2.37M | 1.10M | 7.36M | 12.87M | 21.41M |
| Total Debt | 745.00K | 951.00K | 1.31M | 1.63M | 1.87M | 614.00K |
| Total Liabilities | 3.98M | 2.89M | 4.59M | 4.90M | 5.34M | 4.25M |
| Stockholders Equity | -1.89M | 837.00K | -1.60M | 4.89M | 10.38M | 19.18M |
Cash Flow | ||||||
| Free Cash Flow | -8.46M | -8.03M | -9.99M | -10.63M | -10.48M | -12.39M |
| Operating Cash Flow | -8.45M | -8.03M | -9.97M | -10.56M | -10.37M | -12.36M |
| Investing Cash Flow | -4.00K | -6.00K | -12.00K | -70.00K | -116.00K | -32.00K |
| Financing Cash Flow | 8.01M | 9.30M | 3.73M | 5.12M | 1.95M | 28.21M |
BioCardia Technical Analysis
BioCardia Risk Analysis
BioCardia Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $30.16M | ― | ― | ― | ― | ― | |
48 Neutral | $12.12M | ― | -137.09% | ― | 247.62% | -7.66% | |
45 Neutral | $9.67M | -0.19 | -81.33% | ― | -62.68% | 23.94% | |
43 Neutral | $14.01M | -0.61 | ― | ― | -100.00% | 60.53% | |
41 Neutral | $8.06M | -0.16 | -238.26% | ― | -57.69% | 63.76% |
BioCardia Corporate Events
BioCardia, Inc. has announced that its 2025 Annual Meeting of Stockholders will take place on December 2, 2025, at 9:00 a.m. Pacific Time in Palo Alto, California. The company has set October 8, 2025, as the record date for stockholders eligible to vote and October 17, 2025, as the deadline for stockholder proposals and nominations for the meeting, in compliance with SEC regulations.
The most recent analyst rating on (BCDA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
On October 2, 2025, BioCardia, Inc. announced it has regained compliance with Nasdaq’s Listing Rule 5550(b)(1), ensuring its continued listing on the Nasdaq Stock Market. This achievement follows BioCardia’s efforts to strengthen its financial position by raising capital to support the development of its therapeutic candidates and advance its approved products.
The most recent analyst rating on (BCDA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
On September 22, 2025, BioCardia announced a positive preliminary clinical consultation with Japan’s PMDA regarding the CardiAMP Heart Failure Trial results. This meeting was a preparatory step for a formal consultation on the clinical data’s acceptability for approval submission. The PMDA requested additional information on various aspects of the trial, and BioCardia plans to address these queries before a formal consultation later in the year. This development could potentially enhance BioCardia’s position in the market by enabling access for patients with significant therapeutic needs.
The most recent analyst rating on (BCDA) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
On September 19, 2025, BioCardia, Inc. completed a significant financial transaction by selling 4,800,000 shares of common stock and accompanying warrants, raising approximately $5.1 million in net proceeds. This strategic move, involving key company directors and executive officers, is expected to bolster the company’s financial position and potentially impact its market operations by restricting certain stock issuance activities until March 2026.
The most recent analyst rating on (BCDA) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
On September 18, 2025, BioCardia announced the pricing of a public offering of 4,800,000 shares of common stock and short-term warrants, expected to raise $6 million upfront with potential additional proceeds of $6 million if warrants are fully exercised. The proceeds are intended for working capital and advancing biotherapeutic candidates, with H.C. Wainwright & Co. acting as the exclusive placement agent.
The most recent analyst rating on (BCDA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
On September 18, 2025, BioCardia announced promising results from the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial. The trial’s open label roll-in cohort showed that the therapy was well tolerated and led to significant improvements in exercise tolerance and a reduction in angina episodes at the six-month mark. These results suggest that CardiAMP Cell Therapy could address the unmet needs of patients with chronic myocardial ischemia and refractory angina, potentially enhancing BioCardia’s position in the cardiovascular therapeutics market.
The most recent analyst rating on (BCDA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
The recent earnings call for BioCardia painted a picture of cautious optimism. The company is making significant strides in clinical trials and regulatory pathways, particularly in Japan, with promising partnership discussions on the horizon. However, challenges remain with increased R&D expenses, a rise in net loss, and low cash reserves. The sentiment expressed during the call was one of cautious optimism, with a strong focus on achieving regulatory approvals and forming strategic partnerships to drive future growth.
On August 13, 2025, BioCardia, Inc. and CART-Tech, B.V. announced an exclusive development and commercialization agreement for Heart3D™ Fusion Imaging, aimed at enhancing cardiac biotherapeutic delivery and biopsy procedures. The system, which fuses two-dimensional x-ray images with three-dimensional anatomical heart models, is initially intended for research use and may later be approved for standard clinical practice. This partnership leverages both companies’ expertise and intellectual property, with BioCardia securing exclusive distribution rights for biotherapeutic delivery worldwide and cardiac biopsy in the U.S. The collaboration is expected to improve procedural planning and real-time image precision, potentially generating significant revenue if adopted as a standard of care.
The most recent analyst rating on (BCDA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
BioCardia, Inc., headquartered in Sunnyvale, California, is a biotechnology company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with a unique emphasis on its CardiAMP and CardiALLO cell therapy platforms.
On August 4, 2025, BioCardia, Inc. announced updates on the regulatory approval timeline for its CardiAMP® Cell Therapy System and Helix Transendocardial Delivery Catheter. The company plans to submit a DeNovo 510(k) application for the Helix system to the FDA in Q3 2025, leveraging its safety and performance in numerous clinical studies. Additionally, BioCardia aims to discuss the approval pathway for CardiAMP Cell Therapy for ischemic heart failure with the FDA in Q4 2025, highlighting its previous Breakthrough Designation and clinical trial results. A clinical consultation with Japan’s PMDA is also expected in Q4 2025, potentially facilitating market entry in Japan. These developments could significantly impact BioCardia’s market positioning and provide new opportunities for stakeholders.
The most recent analyst rating on (BCDA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.